{"id":"W2031131661","doi":"10.1007/s12325-013-0060-1","title":"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":520,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; Genentech; AstraZeneca; Amgen; Pfizer; Allergan; Bristol-Myers Squibb; Genomic Health; GlaxoSmithKline","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Internal medicine; Aromatase inhibitor; Breast cancer; Oncology; Clinical endpoint; Placebo; Population; Adverse effect; Progression-free survival; Confidence interval; Cancer; Clinical trial; Aromatase; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01014278,0.0008271852,0.0042304,0.001358239,0.000141641,0.001546486,0.0008153629,0.0007214081,0.003864301],"category_scores_gemma":[0.009740124,0.0004018172,0.007424362,0.0009648338,0.0002851811,0.0006083499,0.000587837,0.001391157,0.0003548742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001144934,"about_ca_system_score_gemma":0.001603873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000929241,"about_ca_topic_score_gemma":0.002574079,"domain_scores_codex":[0.9966471,0.002052254,0.0003938673,0.0003186524,0.0005016249,0.00008658597],"domain_scores_gemma":[0.9942009,0.003397727,0.001561295,0.0002094131,0.0003596343,0.0002711225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3483666,0.0006139127,0.03049159,0.07844315,0.1651375,0.0003438335,0.000280472,0.00511349,0.004117961,0.001484036,0.01051377,0.3550937],"study_design_scores_gemma":[0.2326684,0.07365602,0.2318982,0.01968279,0.348676,0.00253852,0.0002622677,0.009095668,0.002501426,0.004599124,0.07412112,0.0003004816],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1673553,0.8132425,0.001767264,0.002636412,0.0003685164,0.001718002,0.007271568,0.000132165,0.005508323],"genre_scores_gemma":[0.7707456,0.2060192,0.005952688,0.002471744,0.0009307943,0.001567809,0.008577686,0.0000791992,0.003655265],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01014278,"threshold_uncertainty_score":0.05364078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004021741589793851,"score_gpt":0.2567074031613948,"score_spread":0.252685661571601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}